-transparent.png){kind=logo}
Treatment options for rheumatoid arthritis (RA) are expanding as research has provided a more complete understanding of the pathophysiology of the disease. Three disease-modifying agents approved in the last 18 months for early intervention in RA are etanercept, leflunomide, and infliximab. For the relief of the signs and symptoms of RA, the new selective cyclooxygenase-2 (COX-2) inhibitors are joining the available nonsteroidal anti-inflammatory drugs. One COX-2 inhibitor is approved for use in RA, and another is under investigation for that indication. As a class, the COX-2 inhibitors offer efficacy similar to traditional NSAIDs but with less GI and platelet toxicity.
Related Publications
R Infante, and
R G Lahita
January 2002,
Acta medica Austriaca,
R Infante, and
R G Lahita
June 2009,
Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
R Infante, and
R G Lahita
January 2009,
Clinical and experimental rheumatology,
R Infante, and
R G Lahita
December 2001,
The Practitioner,
R Infante, and
R G Lahita
March 1997,
BMJ (Clinical research ed.),
R Infante, and
R G Lahita
December 1983,
Clinics in rheumatic diseases,
R Infante, and
R G Lahita
December 1985,
Drug and therapeutics bulletin,
R Infante, and
R G Lahita
December 1983,
Clinics in rheumatic diseases,
R Infante, and
R G Lahita
June 1993,
Journal of the National Cancer Institute,
R Infante, and
R G Lahita
January 2001,
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
